ISTA Pharmaceuticals

ISTA Pharmaceuticals, Inc.
Industry Pharmaceuticals
Founded 1992
Headquarters Irvine, California
Key people

Vicente Anido Jr., Ph.D., President, Chief Executive Officer, Glenn E. Davis, Vice President, Chief Compliance Officer, Marvin J. Garrett, Vice President, Regulatory Affairs, Quality & Compliance, Kathleen McGinley, Vice President, Human Resources & Corporate Services, Kirk McMullin, Vice President, Operations Timothy R. McNamara, PharmD, Vice President, Clinical Research & Medical Affairs

Tom Mitro, Vice President, Sales & Marketing
Products Bromday, Bepreve, Xibrom, Istalol, Vitrase

ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specializes in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye.[1] ISTA was acquired by Bausch & Lomb on March 26, 2012.[2]

In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.[3]



On May 24, 2013, ISTA Pharmaceuticals entered a guilty plea to federal felony charge of conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. ISTA agreed to pay $33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.[8]


External links

This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.